MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA - METHOTREXATE ALONE COMPARED WITH A COMBINATION OF METHOTREXATE AND CYCLOSPORINE FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE

Authors:
  • RSR STORB
    R STORB
  • HDHJ DEEG
    HJ DEEG
  • VFV FAREWELL
    V FAREWELL
  • KDK DONEY
    K DONEY
  • FAF APPELBAUM
    F APPELBAUM
  • PBP BEATTY
    P BEATTY
  • WBW BENSINGER
    W BENSINGER
  • CBCD BUCKNER
    CD BUCKNER
  • RCR CLIFT
    R CLIFT
  • JHJ HANSEN
    J HANSEN
  • RHR HILL
    R HILL
  • GLG LONGTON
    G LONGTON

  • 1 July 1986
    • journal article
    • research article
    • Vol. 68  (1) , 119-125
    • PMID:3521761
Abstract
Forty-six patients with severe aplastic anemia (median age, 23 years) were treated with high-dose cyclophosphamide followed by infusion of marrow from an HLA-identical family member. To evaluate postgrafting prophylaxis for graft-v-host disease (GVHD), they were entered into a prospective randomized trial comparing the effect of a combination of methotrexate and cyclosporine (n=22) to that of methotrexate alone (n=24). Forty-four of the forty-six patients had evidence of sustained marrow engraftment. Only one patient in each of the two study group showed graft rejection. A significant reduction in the cumulative incidence of grades II to IV acute GVHD was seen in patients given methotrexate/cyclosporine (18%) compared with those given methotrexate alone (53%) (P=.012). IN three patients given methotrexate alone, grade III developed, and in six, grade IV acute GVHD developed, compared with none given methotrexate/cyclosporine. Eighteen of the 22 patiens given methotrexate/cyclosporine and 15 of the 24 given methotrexate alone are alive between 5.5 and 44.5 months (median, 18 months), with actuarial survival rates at 2 years of 82% and 60%, respectively (P= .062). The incidence of fatal infections was higher in patients given methotrexate alone, whereas there are as yet no significant differences in the incidence of chronic GVHD. We conclude that methotrexate/cyclosporine treatment resulted in a significant decrease in the incidence and severity of acute GVHD in patients who received transplants for severe aplastic anemia and thus an improvement in survival.

This publication has 27 references indexed in Scilit: